Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Biosolutions Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$368,671

49 payments

Through program year 2024, Biosolutions Clinical Research Center is reported as receiving $368,671 in research payments, across 49 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $12,300 3
2023 Research $1,157 1
2022 Research $29,522 7
2021 Research $14,143 4
2020 Research $58,993 14
2019 Research $252,556 20

Breakdown

Who paid Research payments · program years 2019–2024
  1. Flexion Therapeutics, Inc. $242,803 8 payments
  2. Regeneron Pharmaceuticals, Inc. $51,273 12 payments
  3. ACADIA Pharmaceuticals Inc $30,679 8 payments
  4. MicroPort Orthopedics Inc $15,254 6 payments
  5. Kiniksa Pharmaceuticals International, plc $12,300 3 payments
  6. Merck Sharp & Dohme Corporation $8,316 3 payments
  7. Sanofi US Services Inc. $3,637 4 payments
  8. E.R. Squibb & Sons, L.L.C. $2,300 1 payment
  9. Pfizer Inc. $1,859 3 payments
  10. Anika Therapeutics, Inc. $250 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Osteoarthritis of the Knee $154,909 1 payment
  2. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $44,912 10 payments
  3. Acp-044-005 $30,679 8 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis $23,117 1 payment
  5. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis $22,774 1 payment
  6. Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip $18,588 1 payment
  7. Post Market Surveillance Study of the Wright Medical Technology Metal on Metal Total Hip System $15,254 6 payments
  8. An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Osteoarthritis of the Knee $13,411 1 payment
  9. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjgren's Disease $12,300 3 payments
  10. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder $8,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record